José Baselga, MD, who resigned his position as the chief medical officer at Memorial Sloan Kettering Cancer Center after failing to disclose millions of dollars in payments from drug companies, is joining AstraZeneca as its head of research and development in oncology; the end of the Affordable Care Act tax penalty on those without health insurance could roll back recent coverage gains for Hispanics, young people, the healthy, and the poor; rural hospitals are forming partnerships with home health agencies in order to survive.
José Baselga, MD, who resigned his position as the chief medical officer at Memorial Sloan Kettering Cancer Center after failing to disclose millions of dollars in payments from drug companies, is joining AstraZeneca as its head of research and development in oncology. The New York Times and ProPublica said that the newly created unit reflects the company’s shift toward cancer treatments. Baselga stepped down in September from his role after the publications revealed he had failed to accurately disclose his conflicts of interest in dozens of articles in medical journals. Baselga is an expert in breast cancer research.
The end of the Affordable Care Act (ACA) tax penalty on those without health insurance could roll back recent coverage gains for Hispanics, young people, the healthy, and the poor, California Healthline reported. It cited a Health Affairs study in which researchers asked more than 3000 Californians who had bought individual healthcare plans: “Would you have purchased health insurance coverage this year if there was no penalty?” Nineteen percent said they would not have, and a disproportionately large number of those were in population groups that were most likely to be uninsured before the ACA took effect. The study concluded that other states could be harder hit than California by the elimination of the penalty.
Rural hospitals are forming partnerships with home health agencies in order to survive, Kaiser Health News reported. Rather than seeing them as a competitor, hospitals are getting creative in order to keep from being penalized for having too many readmissions within 30 days of discharge, which can cost a hospital millions of dollars in penalties and hurt an already-thin bottom line.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen